Phase 1 study of seviteronel, a selective CYP17 lyase and androgen receptor inhibitor, in women with estrogen receptor-positive or triple-negative breast cancer
ConclusionsOnce-daily seviteronel was generally well tolerated in women with and 450 mg QD was chosen as the RP2D.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
More News: Anemia | Breast Cancer | Cancer | Cancer & Oncology | Men | Oral Cancer | Prostate Cancer | Study | Toxicology | Women